Jeanie Cote, MD
Neurology · Owosso, MINPI 1467771311
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $370,376 of the $563,048 with a category attached, or 65.8%. 49 manufacturers reported payments, led by EMD Serono, Inc. at 47.7% of the total. 2025 is the largest year on record at $249,062, more than ten times the $13,275 reported in 2019. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,010 payments — averaging $557.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$269K
- TG Therapeutics, Inc.$65K
- Biogen$56K
- E.r. Squibb & Sons, L.L.C.$44K
- Genentech USA, Inc.$42K
- Ares Trading SA$24K
- plus $63K from 43 others
Across 208 payments — averaging $6180.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$782K
- TG Therapeutics, Inc.$194K
- Genentech, Inc.$152K
- Biogen$99K
- Hoffmann-la Roche Limited$54K
- F. Hoffmann-la Roche AG$5K
- plus $1K from 1 others
What the payments were for
- Consulting fees$110,42420%
- Speaking & faculty fees$370,37666%
- Travel & lodging$61,59811%
- Food & beverage$20,3764%
- Education$2750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$563,048 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 136 | $1,232,911 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 17 | $261,863 |
| EnspryngSatralizumab-Mwge | 13 | $217,048 |
| ZeposiaOzanimod Hydrochloride | 19 | $214,651 |
| CopaxoneGlatiramer Acetate | 30 | $211,131 |
| VumerityDiroximel Fumarate | 16 | $147,490 |
| AubagioTeriflunomide | 12 | $91,276 |
| Dalfampridine ErDalfampridine | 210 | $85,382 |
| TecfideraDimethyl Fumarate | 12 | $84,025 |
| Teriflunomide | 104 | $77,920 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $56,601 |
| MyrbetriqMirabegron | 80 | $41,191 |
| Emgality PenGalcanezumab-Gnlm | 53 | $39,740 |
| Nurtec OdtRimegepant Sulfate | 25 | $37,606 |
| Glatiramer Acetate | 14 | $27,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera | $55,844 | $231,51528 claims |
| Genentech USA, Inc.Enspryng | $42,446 | $217,04813 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $44,110 | $214,65119 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $223 | $211,13130 claims |
| SanofiAubagio | $17,167 | $91,27612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $114 | $56,60116 claims |
| AbbVieQulipta, Ubrelvy | $1,472 | $41,47043 claims |
| PfizerNurtec Odt | $56 | $37,60625 claims |
| Lilly USA, LLCReyvow | $236 | $4,00611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Owosso
- Robert PaceOwosso$693K
- Rosemarie WalchOwosso$563K
- Rany AburashedOwosso$440K
- Margaret FreyOwosso$321K
- Cara LeahyOwosso$185K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.